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PharmacotherapyObjective: The effects of intensive blood pressure (BP) lowering for hypertensive patients
with coronary artery disease (CAD) and diabetes mellitus on their clinical outcomes have
not been fully evaluated. The aim was to explore the optimal systolic BP target in such
patients in a substudy of a prospective, randomized trial.
Methods: Of a total of 2049 hypertensive patients with CAD who were enrolled in the HIJ-
CREATE study, type 2 diabetes was diagnosed in 780 (38.1%). Titration of antihypertensive
agents was performed to reach the target BP of <130/85 mmHg. The primary endpoint
was the occurrence of a first major adverse cardiovascular event (MACE). Achieved BP
was defined as the mean value of systolic BP in patients who did not develop MACEs and
as the mean value of systolic BP prior to MACEs in those who developed MACEs during
follow-up.
Results: During a median follow-up of 4.2 years, the primary outcome occurred in 259
(33.2%) diabetic patients and in 293 (23.1%) non-diabetic patients (p < 0.0001). The diabetic
patients were divided into quartiles based on the mean systolic BP during follow-up. The
relationships between achieved BP and the incidence of MACEs did not follow a J-shaped
curve. Intensive systolic BP lowering to less than 120 mmHg did not correlate with an
increased risk of MACEs.
Conclusions: Our results suggest that the intensive BP lowering may not impair patients’
clinical courses even in a high-risk population. The establishment of an optimal manage-
ment strategy for hypertensive patients with diabetes and CAD is essential.
 2019 Elsevier B.V. All rights reserved.etes–Blood
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Most guidelines for treatment of hypertension recommend a
blood pressure (BP) goal of <140/90 mmHg for hypertensive
patients and a more aggressive goal of <130/80 mmHg for
patients with coronary artery disease (CAD). They were not
drawn from the results of prospective, randomized trials
but based on expert consensus. In the seventh report of
the Joint National Committee (JNC7) on prevention, detec-
tion, evaluation, and treatment of high BP, it is clearly
reported that the relationship between BP and the risk of
cardiovascular events is continuous, consistent, and inde-
pendent of other risk factors [1]. The optimal BP target in
hypertensive patients with CAD is not well defined [2,3].
Subsequently, the JNC7 statement was reviewed and
updated.
Diabetes mellitus is a major cause of cardiovascular dis-
ease, chronic kidney disease, peripheral arterial disease, and
strokes [4,5]. In patients with diabetes, uncontrolled blood
glucose levels are associated with high cardiovascular mor-
bidity and mortality. Sufficient attention to traditional risk
factors could yield further substantive reductions in adverse
events in the diabetic population [6]. In a follow-up study of
Steno-2, the investigators demonstrated that intensive inter-
vention with multiple drug combinations and behavior mod-
ification had sustained beneficial effects with respect to
vascular complications and on mortality rates from any cause
and from cardiovascular causes [7]. Furthermore, the coexis-
tence of hypertension with diabetes strongly exacerbates
the diabetic complications. Recent evidence [7–9] demon-
strates that aggressive glucose and BP control in diabetic
patients with hypertension does not provide any additional
benefits with respect to cardiovascular complications com-
pared to standard glucose and BP control, although the Action
to Control Cardiovascular Risk in Diabetes–Blood Pressure
(ACCORD-BP) study [10] is the only prospective clinical trial
that has evaluated an intensive systolic BP target in diabetic
patients. A recent meta-analysis [11] clearly demonstrated
that contemporary BP lowering was associated with improved
clinical outcomes. However, the authors also pointed out that
the reliability of the meta-analysis was limited by the lack of
sufficient data for aggressive BP lowering in the 120- to 130-
mmHg range.
To date, the optimal BP target in hypertensive patients
with diabetes and coronary artery disease is not well
defined. However, simplification of the antihypertensive
treatment regimen has been launched in the latest guideline
[12,13].
The purpose of the present substudy of a randomized,
controlled trial was to clarify the optimal BP target for
secondary prevention in hypertensive patients with
diabetes and CAD. In particular, the aim was to explore
the optimal systolic BP target in hypertensive patients with
CAD and type 2 diabetes in the prospective, randomized
trial.2. Methods
2.1. Participants
The Heart Institute of Japan Candesartan Randomized Trial
for Evaluation in Coronary Artery Disease (HIJ-CREATE) was
a multicenter, prospective, randomized, controlled study that
compared the effects of candesartan-based therapy to those
of non–angiotensin receptor blocker (ARB)-based standard
therapy on major adverse cardiovascular events in 2049
hypertensive patients with CAD. The study methods and
main results of HIJ-CREATE have been published previously
[14]. In brief, hypertensive patients with angiographically doc-
umented CAD were randomly assigned to receive either
candesartan-based (n = 1024) or non–ARB-based pharma-
cotherapy, including angiotensin-converting enzyme (ACE)
inhibitors (n = 1025). When we started the HIJ-CREATE study,
candesartan was the most common once-a-day ARB pre-
scribed as an antihypertensive in Japan. Therefore, this agent
appeared to be a rational choice for the ARB-based treatment
arm, and its usefulness required evaluation.
2.2. Clinical measures and follow-up
During the median follow-up period of 4.2 years (interquartile
range 3.5–4.9 years), 3 patients in the candesartan arm and 5
in the non-ARB arm were lost to follow-up, resulting in a
follow-up rate of 99.6%. The present trial was conducted in
accordance with the principles of the Declaration of Helsinki.
The institutional review board or relevant ethics committee
of each participating medical center approved the protocol,
andall patientsprovidedwritten, informedconsent before trial
enrollment.
BP was measured using a standard cuff mercury sphygmo-
manometer after 5 min of rest in the sitting position. Hyper-
tension was defined as systolic blood pressure 140 mmHg,
diastolic blood pressure 90 mmHg, or a history of having
received treatment for hypertension at the time of enrollment.
Diabeteswas defined as a fasting blood glucose level126 mg/
dL or treatment with hypoglycemic agents at the time of
enrollment. Titration of antihypertensive agents was per-
formed to reach the target blood pressure of <130/85 mmHg.
Participantswere followed by hospital doctors or other general
practitioners. Incidence of endpoint events in addition to drug
safety information was determined during the scheduled 6,
12, 24, 36, 48, and 60-month visits. In diabetic participants, gly-
cosylated hemoglobin (HbA1c) was also measured during the
scheduled 6, 12, 24, 36, 48, and 60-month visits.
All patients were followed for 36 months. Blood pressure
values from baseline to the time of the event or to the last pro-
tocol visit were used for the analysis. The primary endpoint of
HIJ-CREATE was the time to first major adverse cardiac event
(MACE; a composite of cardiovascular death, non-fatal
myocardial infarction, unstable angina, heart failure, stroke,
and other cardiovascular events requiring hospitalization).
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Participants were divided into quartiles based on their aver-
age levels of systolic and diastolic BP during follow-up. Cumu-
lative event-free survival was measured by the method of
Kaplan-Meier, and unadjusted differences were compared
using the log-rank test. The relationship between achieved
BP divided into quartiles and the risk of MACE was explored
using a Cox proportional hazard regression model. It was
desirable to include the traditional risk factors that were
determined by reference to previous studies [15,16] in the pro-
portional hazard model. Multivariate analysis using the Cox
proportional hazards model was performed to assess the rela-
tionship of the following baseline characteristics to subse-
quent MACEs: male sex, age, number of diseased coronary
arteries, estimated glomerular filtration rate, HbA1c level dur-
ing the study period, and pharmacotherapy. The interaction
of hypertension with the effect of antihypertensive medical
therapy was analyzed using a likelihood ratio test. Adjusted
hazard ratios (HRs) with 95% CIs were calculated for MACEs.
Statistical analysis was conducted at an independent statisti-
cal data center (Medical TOUKEI Corporation, Tokyo, Japan)
using SPSS 15.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.1.3
(SAS Institute Inc., Cary, NC, USA).
3. Results
In the HIJ-CREATE study, a total of 2049 angiographically doc-
umented CAD patients with hypertension were recruited. The
participants were followed-up prospectively on a regular basis
to June 2007. During a median follow-up of 4.2 years, 8
patients were lost to follow-up, resulting in a follow-up rate
of 99.6%. Of the 2049 participants, diabetes was diagnosed
in 780 (Fig. 1). Baseline characteristics of the patients are
shown in Table 1. Compared with the non-diabetic patients,
the diabetic group had a higher prevalence of silent myocar-
dial ischemia and multi-vessel coronary artery disease. Left
ventricular ejection fraction was significantly lower in the
diabetic group patients than that in the non-diabetic group
patients (53.3% vs. 55.0%).Randomization
(n=2049)
Fig. 1 – Study profile.Table 2 shows mean systolic and diastolic BPs in both
groups during the follow-up period. Mean systolic BP at base-
line was 136.6 mmHg in the diabetic group and 134.5 mmHg
in the non-diabetic group (p = 0.01). During follow-up after
randomization, mean systolic BPs did not differ between the
two groups throughout the trial (p = 0.999). On the other hand,
mean diastolic BPs were significantly lower in patients with
diabetes than in patients without diabetes throughout the
entire period.
During the follow-up period, the primary outcome
occurred in 259 (33.2%) diabetic patients and in 293 (23.1%)
non-diabetic patients. The diabetic group showed a signifi-
cantly higher incidence of MACEs than the non-diabetic
group (p < 0.0001 by the log-rank test, Fig. 2). Table 3 shows
serial changes of HbA1c in the diabetic group during the
follow-up period. These results indicate that intensive hypo-
glycemic therapy was not conducted for the patients with dia-
betes during the study period.
In both diabetic and non-diabetic groups, average systolic
BP levels during the study period were significantly higher in
patients who experienced MACEs than in patients without
MACEs (132.8 mmHg vs. 136.7 mmHg in the diabetic group,
p < 0.001; 132.3 mmHg vs. 134.2 mmHg in the non-diabetic
group, p = 0.036, Fig. 3). On the other hand, the mean diastolic
BP levels during the study period in both groups showed no
significant differences regardless of whether they experi-
enced MACEs (74.6 mmHg vs. 74.0 mmHg in the diabetic
group, p = 0.389; 76.4 mmHg vs. 75.6 mmHg in the non-
diabetic group, p = 0.172, Fig. 4).
To explore the optimal BP level in hypertensive patients
with CAD and diabetes, they were evaluated retrospectively.
The participants were divided into quartiles based on the
average systolic BPs during the study period. In hypertensive
patients with CAD and diabetes, poor control of systolic BP
(mean > 140 mmHg during the study period) was associated
with a significantly increased incidence of MACEs compared
with the well-controlled and modestly controlled groups
(95% confidence interval, 1.35–2.67). On the other hand, inten-
sive systolic BP lowering (mean  120 mmHg during the study
period) was not correlated with an increased risk of subse-
quent MACEs (95% confidence interval, 0.55–1.50). The rela-
tionships between achieved systolic BP and the incidence of
MACEs did not follow J-shaped curves in hypertensive
patients with CAD and diabetes (Fig. 5).
The effects of systolic BP control on subsequent adverse
events were evaluated in hypertensive patients with CAD
and diabetes. There were 259 MACEs and 59 any-cause death
cases. The participants were divided into equal quartiles
based on themean systolic BPs during the study period. There
were lower risks of unstable angina, congestive heart failure,
and stroke, which resulted in a good outcome, with moderate
BP lowering during the study period.
In terms of the effect of the intensity of blood pressure
reduction on study outcomes, well-controlled systolic BP
(mean  134 mmHg during the study period) was associated
with a 42% reduction in the odds comparedwith the modestly
controlled group. In particular, the incidences of unstable
angina, congestive heart failure, and stroke were significantly
lower in the modestly controlled systolic BP group.
Table 1 – Subjects’ baseline characteristics.
With diabetes (n = 780) Without diabetes (n = 1269) p-value
Number (%) Number (%)
Male 614 (78.7) 1030 (81.2) 0.18
Age, y (mean ± SD) 64.9±8.9 64.7 ± 9.4 0.65
Acute myocardial infarction 119 (15.3) 203 (16.0) 0.07
Stable angina 194 (24.9) 333 (26.2) 0.49
Silent myocardial ischemia 153 (19.6) 138 (10.9) <0.0001
Acute coronary syndrome 263 (33.7) 461 (36.3) 0.23
Number of diseased vessels
1 313 (40.1) 560 (44.1)
2 236 (30.3) 335 (26.4) <0.0001
3 148 (19.0) 162 (12.8)
Percutaneous coronary intervention 664 (85.1) 1032 (81.3) 0.03
Coronary artery bypass grafting 114 (14.6) 122 (9.6) <0.0001
Hypercholesterolemia 523 (67.1) 693 (54.6) <0.0001
Smoker 497 (63.7) 790 (62.3) 0.51
Peripheral vascular disease 32 (4.1) 32 (2.5) 0.049
Blood pressure at enrollment, mmHg
Systolic (mean ± SD) 136.6 ± 16.9 134.5 ± 18.6 0.010
Diastolic (mean ± SD) 74.8 ± 11.2 76.2 ± 12.3 <0.01
NYHA functional class
I 622 (79.7) 1005 (79.2) 0.77
II 158 (20.3) 264 (20.8)
LVEF (mean ± S.D., %) 53.3 ± 11.2 55.0 ± 10.7 <0.001
Body mass index (mean ± S.D.), kg/m2 24.8 ± 3.2 24.5 ± 2.9 0.03
Estimated GFR (MDRD, mean ± S.D.), ml/min/1.73 m2 62.3 ± 19.3 61.9 ± 17.5 0.65
Aspirin 714 (91.5) 1169 (92.1) 0.64
ARB 374 (47.9) 639 (50.4) 0.29
ACE inhibitors 308 (39.5) 423 (33.3) 0.005
Calcium-channel antagonists 410 (52.6) 621 (48.9) 0.11
Statins 385 (49.4) 521 (41.1) <0.001
Diuretics 90 (11.5) 95 (7.5) 0.002
Beta blockers 405 (51.9) 565 (44.5) 0.001
Specific antidiabetic drugs
Oral hypoglycemic agents 350 (44.9) N.A.
Insulin 107 (13.7) N.A.
ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blocker, GFR: glomerular filtration rate, LVEF: left ventricular ejection fraction,
MDRD: Modification of Diet in Renal Disease, NYHA: New York Heart Association.
Table 2 – Blood pressure during follow-up (mean ± S.D., mmHg).
Months after randomization Non-diabetic Number Diabetic Number p
Systolic blood pressure
Baseline 134.5 ± 18.6 1268 136.6 ± 16.9 780 0.01
6 131.9 ± 17.3 1219 133.3 ± 17.4 753 N.S.
12 133.3 ± 16.5 1167 132.1 ± 16.2 724 N.S.
24 131.7 ± 16.9 1129 131.6 ± 17.5 710 N.S.
36 131.2 ± 15.6 1082 131.8 ± 17.7 682 N.S.
48 130.4 ± 15.3 765 132.1 ± 16.1 498 N.S.
60 131.5 ± 15.5 391 131.4 ± 16.7 250 N.S.
Diastolic blood pressure
Baseline 76.2 ± 12.3 1268 74.8 ± 11.2 780 <0.01
6 75.8 ± 11.2 1218 74.4 ± 11.1 753 <0.01
12 77.1 ± 10.6 1167 73.8 ± 10.2 724 <0.001
24 76.4 ± 11.1 1129 74.0 ± 10.6 709 <0.001
36 76.1 ± 10.2 1079 74.0 ± 10.9 682 <0.001
48 75.6 ± 10.5 764 73.1 ± 10.1 493 <0.001
60 75.1 ± 10.5 389 71.7 ± 11.1 250 <0.001
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Fig. 2 – Unadjusted clinical outcomes of participants with or
without diabetes Kaplan-Meier estimates demonstrate that
hypertensive patients with coronary artery disease and
diabetes have significantly poorer outcome than those
without diabetes.
Table 3 – Glycosylated haemoglobin (HbA1c) in patients with
diabetes during follow-up (mean ± S.D.).
Months after randomization HbA1c (%) Number
Baseline 6.98 ± 1.38 638
6 6.83 ± 1.32 681
12 6.87 ± 1.38 652
24 6.92 ± 1.23 646
36 7.03 ± 1.34 604
48 7.02 ± 1.29 432
60 7.01 ± 1.19 207
140
130
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mmHg
140
130
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mmHg
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Fig. 3 – Baseline and post-baseline measurements of
systolic blood pressure over time During the follow-up
period, systolic blood pressures show no significant
differences between the two groups.
80
70
p = 0.389
mmHg
80
70
p = 0.172
mmHg
setebaiDtuohtiWsetebaiDhtiW
74.6 74.0
76.4 75.6
Mean Diastolic Blood Pressure during Follow-up
MACE (-) MACE (+)
(n = 521) (n = 259)
MACE (-) MACE (+)
(n = 976) (n = 292)
Fig. 4 – Baseline and post-baseline measurements of
diastolic blood pressure over time During the follow-up
period, diastolic blood pressures are significantly higher in
non-diabetic patients than in diabetic patients.
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Fig. 5 – Risk of MACEs in hypertensive patients with
coronary artery disease and diabetes, according to achieved
systolic blood pressure expressed as the average systolic
blood pressure during the study period. The relationships
between achieved systolic BP and the incidence of MACEs
do not follow J-shaped curves in hypertensive patients with
coronary artery disease and diabetes.
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model. Higher achievement of the systolic BP goal was associ-
ated with a lower incidence of MACEs. On the other hand,glycemic control showed no relationship with the incidence
of MACEs, except for poor control of diabetes, defined as
mean HbA1c  7.6% during the study period.
4. Discussion
In hypertensive patients with diabetes and CAD, the results of
the post hoc analysis of the prospective, randomized trial
showed that the relationship between achieved systolic BP
and the incidence of MACEs did not follow a J-shaped curve,
and suggest that the moderate to intensive BP-lowering regi-
men of the contemporary era may not impair patients’ clini-
cal courses even in such a high-risk population. In addition,
modest glycemic control may not increase the incidence of
adverse events in such a high-risk population.
The roles of diabetes and hypertension as risk factors for
cardiovascular events are well established [17–19]. A meta-
Table 4 – Univariate and multivariate analyses for major adverse cardiovascular events (patients with diabetes).
Univariate Multivariate
HR 95% CI p HR 95% CI p
Male 0.97 (0.72–1.31) 0.84
Age, 60  < 70 y 1.34 (0.97–1.86) 0.08 1.13 (0.81–1.60) 0.47
70 y 1.58 (1.15–2.19) 0.005 1.37 (0.98–1.91) 0.07
Number of diseased vessels
2 2.83 (1.58–5.07) <0.001 2.29 (1.26–4.18) 0.007
3 3.71 (2.05–6.72) <0.001 2.75 (1.49–5.08) 0.001
Estimated GFR (MDRD)
60 ml/min/1.73 m2 0.77 (0.60–0.98) 0.034 0.90 (0.66–1.22) 0.48
Attainment of BP goals
25%  < 50% 0.36 (0.24–0.55) <0.001 0.35 (0.22–0.53) <0.001
50% 0.30 (0.21–0.43) <0.001 0.30 (0.21–0.44) <0.001
Hb A1c
6.1%  < 6.8% 0.91 (0.63–1.33) 0.63 0.88 (0.60–1.28) 0.50
6.8%  < 7.6% 1.09 (0.75–1.59) 0.64 1.05 (0.72–1.53) 0.81
7.6% 1.40 (0.98–2.00) 0.06 1.24 (0.86–1.80) 0.24
Non-ARB standard therapy 1.08 (0.81–1.44) 0.57
ACE inhibitors 1.11 (0.86–1.41) 0.43
Beta blockers 1.36 (1.06–1.73) 0.02 1.19 (0.93–1.53) 0.17
Calcium-channel antagonists 0.91 (0.72–1.16) 0.46
Diuretics 1.59 (1.13–2.20) 0.007 1.41 (0.98–2.02) 0.07
ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blocker, BP: blood pressure, GFR: glomerular filtration rate, MDRD: Modifi-
cation of Diet in Renal Disease.
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pre-existing cardiovascular disease indicated that deaths
from cardiovascular disease increase progressively and lin-
early with blood pressure [20]. Consequently, ‘‘the lower, the
better” theory in blood pressure lowering therapy for hyper-
tensive patients has been widely accepted in the manage-
ment of hypertension for primary prevention [21]. During
the last decade, this linear theory has been challenged, espe-
cially in patients with CAD [10,22–24]. Especially, in the
ACCORD trial [10], which compared a target of lower than
120 mmHg to a target lower than 140 mmHg, the investigators
demonstrated no significant reduction in the composite out-
come of cardiovascular death, nonfatal myocardial infarction,
and nonfatal stroke. Furthermore, the investigators of ONgo-
ing Telmisartan Alone and in combination with Ramipril Glo-
bal Endpoint Trial (ONTARGET) demonstrated that there was
no benefit in the incidence of cardiovascular outcomes by
aggressive BP lowering below 130 mmHg in diabetic patients
with hypertension [25]. Although it is hard to explain this
apparently paradoxical association in such a high-risk popu-
lation, some studies have suggested that tight blood pressure
control might increase cardiovascular risk by the underperfu-
sion of vital organs [26,27]. Data on the risk of adverse events
from randomized trials of intensive versus modest BP lower-
ing regimens for secondary prevention populations are lim-
ited. In the present study, all participants underwent
appropriate evaluation with coronary angiography and revas-
cularization as needed. Consequently, the moderate to inten-
sive BP lowering regimen might have caused no harm in the
present participants. The magnitude of the increased risk
associated with intensive BP lowering strategies for this
high-risk population may be small in combination with ade-quate coronary revascularizations and modern pharma-
cotherapy (including aspirin and statins). Although previous
studies [24,28] have demonstrated a J-shaped relationship
between BP and cardiovascular events, the risk was relatively
flat for systolic BPs between 110 and 140 mmHg, and excess
risk was seen at systolic BPs < 110 mmHg. The results of the
present study are consistent with these results.
In the secondary analyses of ONTARGET and TRANSCEND
[29], the investigators demonstrated that a diastolic BP of 70–
80 mmHg was associated with the lowest event rate in
patients with controlled systolic BP, whereas there was
increased risk among those with both lower and higher dias-
tolic BPs. These data suggest that cardiovascular risk may be
defined by diastolic BP levels, despite optimally achieved sys-
tolic BP levels. In patients with hypertension, the Framing-
ham Heart Study also found that the same cutoff point of
diastolic BP was associated with increased cardiovascular
events. Furthermore, the investigators showed that the risk
was increased among those with both low diastolic BP and a
wide pulse pressure [30]. The results of the present study,
which showed that low diastolic BP and wide pulse pressure
were associated with increased risk, were consistent with
those of the previous studies.
Previous studies demonstrated the U-shaped relationship
between HbA1c and subsequent cardiovascular events and
mortality [31–33]. Previous studies clearly demonstrated the
validity of a ‘‘sweet spot” for controlling glycemia in primary
prevention [34,35]. In the present study, the results also sug-
gest that moderate glycemic control, defined as mean
HbA1c  7.5%, during the study period correlates with favor-
able outcomes for secondary prevention. A larger scale,
prospective, randomized trial is required to elucidate the rela-
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adverse events in hypertensive patients with CAD and
diabetes.
We previously reported that the modern pharmacotherapy
with aspirin and renin-angiotensin blockers combined with
acute revascularization may improve the prognosis of dia-
betic patients with acute myocardial infarction [36]. It has
been previously demonstrated that the association of antihy-
pertensive medications with incident diabetes was lowest for
renin-angiotensin blockers, followed by calcium blockers,
beta blockers, and diuretics in rank order [37]. Although
renin-angiotensin receptor blocker use led to significant risk
reductions in the incidence of diabetes in a high-risk popula-
tion [14,38], the investigators of Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes Research (NAVIGA-
TOR) clearly demonstrated that such pharmacotherapy did
not reduce the rate of cardiovascular events [38], and some-
times it causes concerns about the increased risk of myocar-
dial infarction [39]. In a recent network meta-analysis,
although renin-angiotensin receptor blockers were the most
effective agents against end-stage kidney disease for diabetic
patients, the investigators showed that no BP-lowering thera-
peutic modality in the contemporary era improved survival in
such a population [40]. The results of the present study sug-
gest that the use of renin-angiotensin receptor blockers does
not improve the outcomes of hypertensive patients with CAD
and diabetes.
In the Japanese Primary Prevention of Atherosclerosis
With Aspirin for Diabetes (JPAD) Trial [41], the investigators
demonstrated that aspirin use for type 2 diabetic patients
had no clear benefit from the perspective of bleeding risk
and cardiovascular event prevention. Furthermore, the inves-
tigators of the A Study of Cardiovascular Events in Diabetes
(ASCEND) study [42] concluded that aspirin use is not recom-
mended in persons with diabetes and no evident cardiovascu-
lar disease, balancing the bleeding risk and the primary
prevention of cardiovascular disease. The HIJ-CREATE study
was started before such evidence had been established. On
the other hand, it is well established that aspirin use is bene-
ficial for secondary prevention in patients with cardiovascular
disease [43]. In the present study, because 83% of the HIJ-
CREATE participants underwent coronary interventions, more
than 90% of them were prescribed aspirin. Thus, the useful-
ness of aspirin for hypertensive patients with CAD and dia-
betes was not evaluated.
5. Study limitations
It must be emphasized that this was a post hoc analysis of a
prospective, randomized study, the HIJ-CREATE study, which
was not designed to investigate the risk of diabetic patients
with CAD and hypertension as a primary outcome. Although
the results were statistically significant, the wide confidence
intervals for the hazard ratios prevent any firm conclusions.
The present study may be still underpowered due to low
event rates. This study was retrospective and based on a sub-
group analysis of a prospective study, and a post hoc power
calculation was not performed. The results must, therefore,
be interpreted with caution. Because the sample size mayhave been inadequate for making any conclusions, further
larger-scale, prospective, randomized studies are needed to
reach any conclusions. Because it was not a predefined study
objective to evaluate the effects of antidiabetic treatment, the
diagnosis of diabetes was based on history obtained at enroll-
ment. Furthermore, the details of specific antidiabetic medi-
cations and their adherence were not fully investigated. The
number of study subjects was small. Furthermore, in the
absence of an appropriate power calculation, the study power
of the present post hoc analysis might have been insufficient.
In conclusion, the present study suggests that the exces-
sive BP lowering regimen of the contemporary era may not
impair the clinical courses of hypertensive patients with
CAD and diabetes. Nonetheless, along with BP-lowering ther-
apy, further prospective, randomized studies are needed to
establish the optimal management strategy for hypertensive
patients with diabetes and CAD.
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